RNAZ today
$1.40+$0.05 (+3.70%)close Nov 17, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourDescending Triangle
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $1.95
Key levels
Resistance$1.91
Resistance$1.55
Support$1.33
Latest news & SEC filings
NewsTransCode Therapeutics hires Tungsten Advisors for strategic review
All RNAZ news →About Transcode Therapeutics
Transcode Therapeutics develops RNA-based drugs and immune-focused cancer therapies, aimed at serious and late-stage tumors. Its main candidate, TTX-MC138, targets a cancer-linked microRNA and has finished an early human study. The company is also pursuing a vaccine candidate, a virus-based immune therapy program, and, via its Polynoma unit, the experimental melanoma vaccine Seviprotimut-L. It serves cancer patients and is based in the United States.
Based on the company's 10-K filed Apr 15, 2026.
Nasdaq · Healthcare
Transcode Therapeutics, Inc. (RNAZ)
What Is the Price Target for RNAZ?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is RNAZ a Buy or Sell Right Now?
Test your own strategy on RNAZ
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on RNAZ with SEPT’s own market data.
Start Free Trial →Is RNAZ Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B
Fair Value
$1.76
9
Moat Score
NONE
4/9
Piotroski Score
-1.2
Altman Z-Score
What Is Smart Money Doing with RNAZ?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →RNAZ Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
96.07%
FCF Growth YoY
-46.1%
Revenue Trend
UNKNOWN
Dark Pool Trades for RNAZ
PREVIEWRecent off-exchange (dark pool) prints for RNAZ: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:39:26 | $1.39 | 1,000 | $$1K | SELL |
| 20:04:15 | $1.40 | 1,000 | $$1K | SELL |
| 19:53:00 | $1.53 | 1,500 | $$2K | BUY |
| 19:52:13 | $1.48 | 2,000 | $$3K | BUY |
| 19:31:47 | $1.37 | 1,000 | $$1K | SELL |
5 dark pool trades shown · $$9K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Transcode Therapeutics, Inc. (RNAZ) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →RNAZ — frequently asked questions
What is RNAZ stock price today?
Transcode Therapeutics, Inc. (RNAZ) is at $1.40, up 3.70% (+$0.05) at the Nov 17, 2026 close.
Why is RNAZ stock moving today?
Latest RNAZ news — Oct 29, 2026: TransCode Therapeutics hires Tungsten Advisors for strategic review
Did RNAZ beat earnings?
RNAZ last reported on Aug 14, 2026: EPS -$7.17.
What are RNAZ support and resistance levels?
Support: $1.33. Resistance: $1.55, $1.91, $2.39.
What are insiders doing with RNAZ?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on RNAZ?
Oct 29, 2026: TransCode Therapeutics hires Tungsten Advisors for strategic review